Calidi Biotherapeutics (NYSE:CLDI) Shares Down 8.2% – Here’s What Happened

Calidi Biotherapeutics, Inc. (NYSE:CLDI)’s stock price fell 8.2% during mid-day trading on Wednesday . The company traded as low as $1.30 and last traded at $1.35. 1,961,157 shares were traded during mid-day trading, an increase of 37% from the average session volume of 1,435,489 shares. The stock had previously closed at $1.47.

Calidi Biotherapeutics Stock Performance

The firm has a 50 day moving average price of $1.75.

Calidi Biotherapeutics (NYSE:CLDI) last announced its earnings results on Tuesday, November 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.20. On average, research analysts predict that Calidi Biotherapeutics, Inc. will post -4.48 EPS for the current year.

Institutional Trading of Calidi Biotherapeutics

A hedge fund recently raised its stake in Calidi Biotherapeutics stock. Delta Investment Management LLC boosted its position in Calidi Biotherapeutics, Inc. (NYSE:CLDI) by 1,955.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 210,230 shares of the company’s stock after acquiring an additional 200,000 shares during the quarter. Delta Investment Management LLC owned 0.41% of Calidi Biotherapeutics worth $42,000 as of its most recent filing with the Securities and Exchange Commission. 12.53% of the stock is owned by institutional investors.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.